CareDx (CDNA) Competitors

CareDx (NASDAQ:CDNA) and Fulgent Genetics (NASDAQ:FLGT) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, media sentiment, profitability, valuation, institutional ownership, dividends, community ranking, risk and analyst recommendations.

Does the media favor CDNA or FLGT?

In the previous week, Fulgent Genetics had 1 more articles in the media than CareDx. MarketBeat recorded 4 mentions for Fulgent Genetics and 3 mentions for CareDx. CareDx's average media sentiment score of 0.53 beat Fulgent Genetics' score of 0.36 indicating that CareDx is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CareDx	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Fulgent Genetics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Which has higher earnings and valuation, CDNA or FLGT?

Fulgent Genetics has higher revenue and earnings than CareDx. CareDx is trading at a lower price-to-earnings ratio than Fulgent Genetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CareDx	$280.32M	4.25	-$190.28M	-$2.70	-8.22
Fulgent Genetics	$289.21M	1.84	-$167.82M	-$5.52	-3.14

Do analysts rate CDNA or FLGT?

CareDx presently has a consensus target price of $29.60, suggesting a potential upside of 33.33%. Fulgent Genetics has a consensus target price of $28.50, suggesting a potential upside of 64.27%. Given Fulgent Genetics' higher probable upside, analysts plainly believe Fulgent Genetics is more favorable than CareDx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CareDx	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Fulgent Genetics	0 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Is CDNA or FLGT more profitable?

CareDx has a net margin of -45.90% compared to Fulgent Genetics' net margin of -59.39%. Fulgent Genetics' return on equity of -1.81% beat CareDx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CareDx	-45.90%	-53.70%	-30.42%
Fulgent Genetics	-59.39%	-1.81%	-1.66%

Do insiders & institutionals have more ownership in CDNA or FLGT?

48.1% of Fulgent Genetics shares are held by institutional investors. 4.9% of CareDx shares are held by insiders. Comparatively, 31.8% of Fulgent Genetics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Which has more risk & volatility, CDNA or FLGT?

CareDx has a beta of 1.8, suggesting that its stock price is 80% more volatile than the S&P 500. Comparatively, Fulgent Genetics has a beta of 1.51, suggesting that its stock price is 51% more volatile than the S&P 500.

Does the MarketBeat Community believe in CDNA or FLGT?

CareDx received 196 more outperform votes than Fulgent Genetics when rated by MarketBeat users. Likewise, 66.17% of users gave CareDx an outperform vote while only 60.25% of users gave Fulgent Genetics an outperform vote.

Company	Underperform	Outperform
CareDx	Outperform Votes 440 66.17%	Underperform Votes 225 33.83%
Fulgent Genetics	Outperform Votes 244 60.25%	Underperform Votes 161 39.75%

Summary

CareDx and Fulgent Genetics tied by winning 9 of the 18 factors compared between the two stocks.